{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:08:36Z","timestamp":1771304916219,"version":"3.50.1"},"reference-count":39,"publisher":"Tech Science Press","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2013,10,21]]},"abstract":"<jats:p>Anti-CD20 monoclonal antibodies have revolutionized the treatment of non-Hodgkin\u2019s lymphoma over the last decade. Unfortunately, a significant number of patients treated by these antibodies exhibit innate or acquired antibody resistance and fail to respond to treatment. Strategies to improve antibody function and overcome resistance include the development of new \u201cengineered\u201d antibodies and the use of new drug combination therapies. In this report, we show that the antimetabolite hydroxyurea significantly enhances the ability of two therapeutic monoclonal antibodies to directly kill some human B-cells. The two anti-CD20 antibodies studied were a clinically well-established type 1 therapeutic antibody, namely rituximab and GA101, an antibody representing the new breed of type 2 glycoengineered monoclonals. Hydroxyurea specifically enhanced the direct caspase-independent killing pathway of both of these antibodies as exemplified by the resistance to broad spectrum caspase inhibitors, lack of internucleosomal DNA laddering, and lack of activation of caspases 3, 8, and 9. Both rituximab and GA101 appear to preferentially kill cells in the G<jats:sub>0<\/jats:sub>\/G<jats:sub>1<\/jats:sub>cell cycle phase. One of the many reported effects of hydroxyurea is cell arrest in this phase. Arresting antibody-sensitive cells in this stage of the cell cycle by means other than hydroxurea also sensitized the cells to caspase-independent antibody-mediated death, suggesting that the potentiating effect of hydroxyurea may be mediated via its effects upon the cell cycle. The possible combination of hydroxyurea and anti-CD20 monoclonal antibodies may offer new possibilities for combination therapies in the clinic.<\/jats:p>","DOI":"10.3727\/096504013x13728687793353","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T01:09:50Z","timestamp":1382058590000},"page":"545-555","source":"Crossref","is-referenced-by-count":4,"title":["Hydroxyurea Potentiates the Caspase-Independent Killing of B-Cell Lines by Rituximab and GA101"],"prefix":"10.32604","volume":"20","author":[{"given":"Ian","family":"Daniels","sequence":"first","affiliation":[{"name":"David Evans Medical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmunem","family":"Abulayha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","reference":[{"key":"b1","first-page":"251","article-title":"CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin\u2019s lymphoma","volume":"67","year":"2009","journal-title":"Neth. J. Med."},{"key":"b2","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1182\/blood-2010-07-293407","article-title":"A decade of R-CHOP","volume":"116","year":"2010","journal-title":"Blood"},{"key":"b3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"b4","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: Safety and efficacy of retreatment","volume":"18","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"b5","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance","volume":"22","year":"2003","journal-title":"Oncogene"},{"key":"b6","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: Synergistic direct antiproliferative and apoptotic effects","volume":"100","year":"2002","journal-title":"Blood"},{"key":"b7","first-page":"836","article-title":"Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin\u2019s lymphoma","volume":"8","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"b8","first-page":"75","article-title":"Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B-cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab","volume":"134","year":"2006","journal-title":"Br. J. Haematol."},{"key":"b9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4161\/cbt.13.2.18876","article-title":"Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab","volume":"13","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"b10","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","year":"2005","journal-title":"Oncogene"},{"key":"b11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\u03baB signaling pathway in non-Hodgkin\u2019s lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","year":"2005","journal-title":"Cancer Res."},{"key":"b12","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1158\/0008-5472.CAN-03-3500","article-title":"Inhibition of the Raf-MEK1\/2-ERK1\/2 signaling pathway, Bcl-xL downregulation, and chemosensitization of non-Hodgkin\u2019s lymphoma B-cells by Rituximab","volume":"64","year":"2004","journal-title":"Cancer Res."},{"key":"b13","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4049\/jimmunol.175.4.2174","article-title":"Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin\u2019s lymphoma cell line via inhibition of NF-kappa B activity: Role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively","volume":"175","year":"2005","journal-title":"J. Immunol."},{"key":"b14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type 1 and 2 monoclonal antibodies","volume":"47","year":"2010","journal-title":"Semin. Hematol."},{"key":"b15","first-page":"4393","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type 2 anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity","volume":"115","year":"2003","journal-title":"Blood"},{"key":"b16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"b17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/era.11.175","article-title":"Hydroxyurea: A key player in cancer chemotherapy","volume":"12","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"b18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/emm.2004.62","article-title":"Involvement of mitogen-activated protein kinases and p21Waf1 in hydroxyurea-induced G1 arrest and senescence of McA-RH7777 rat hepatoma cell line","volume":"36","year":"2004","journal-title":"Exp. Mol. Med."},{"key":"b19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jmv.20130","article-title":"Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt\u2019s lymphoma cell line Raji","volume":"73","year":"2004","journal-title":"J. Med. Virol."},{"key":"b20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4889(92)90076-N","article-title":"Hydroxyurea induces apoptosis and regular DNA fragmentation in a Burkitt\u2019s lymphoma cell line","volume":"1136","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"b21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.1995.13.5.1089","article-title":"Phase I\/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma","volume":"13","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"b22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.1987.5.3.419","article-title":"Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin\u2019s lymphoma","volume":"5","year":"1987","journal-title":"J. Clin. Oncol."},{"issue":"Pt. 2","key":"b23","first-page":"457","article-title":"Cell-cycle-dependent changes in ceramide levels preceding retinoblastoma protein dephosphorylation in G2\/M","volume":"334","year":"1998","journal-title":"Biochem. J."},{"key":"b24","first-page":"23","article-title":"Apoptosis induction in fludarabine resistant malignant B-1 cells by G2\/M cell cycle arrest","volume":"5","year":"1998","journal-title":"Oncol. Rep."},{"key":"b25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10495-006-6314-5","article-title":"Caspase-independent killing of Burkitt lymphoma cell lines by rituximab","volume":"11","year":"2006","journal-title":"Apoptosis"},{"key":"b26","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type 2 anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","year":"2011","journal-title":"Blood"},{"key":"b27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"b28","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases","volume":"87","year":"2002","journal-title":"Haematologica"},{"key":"b29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/excr.1998.4158","article-title":"Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM","volume":"244","year":"1998","journal-title":"Exp. Cell. Res."},{"key":"b30","first-page":"235","article-title":"Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line","volume":"14","year":"2004","journal-title":"Oncol. Res."},{"key":"b31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajh.20542","article-title":"Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib","volume":"81","year":"2006","journal-title":"Am. J. Hematol."},{"key":"b32","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/jnci\/80.17.1412","article-title":"Hydroxyurea and etoposide: In vitro synergy and phase I clinical trial","volume":"80","year":"1988","journal-title":"J. Natl. Cancer Inst."},{"key":"b33","first-page":"84","article-title":"Laboratory and clinical studies of biochemical modulation by hydroxyurea","volume":"19","year":"1992","journal-title":"Semin. Oncol."},{"key":"b34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1440-1827.2004.01678.x","article-title":"Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression","volume":"54","year":"2004","journal-title":"Pathol. Int."},{"key":"b35","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/sj.bjc.6604388","article-title":"Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma","volume":"98","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"Pt. 7","key":"b36","first-page":"1481","article-title":"Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt\u2019s lymphoma cell line","volume":"71","year":"1990","journal-title":"J. Gen. Virol."},{"key":"b37","doi-asserted-by":"crossref","first-page":"e28506","DOI":"10.1371\/journal.pone.0028506","article-title":"Latent Epstein-Barr virus can inhibit apoptosis in B-cells by blocking the induction of NOXA expression","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"b38","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/sj.onc.1207253","article-title":"The EBNA-3 gene family proteins disrupt the G2\/M checkpoint","volume":"23","year":"2004","journal-title":"Oncogene"},{"key":"b39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jmv.10384","article-title":"Contrasting effects of hydroxyurea on cell growth and reduction in Epstein-Barr virus genomes in EBV-infected epithelioid cell lines vs. Burkitt\u2019s lymphoma cell lines","volume":"70","year":"2003","journal-title":"J. Med. Virol."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/cog\/or\/2013\/00000020\/00000012\/art00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T19:16:49Z","timestamp":1716059809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.3727\/096504013X13728687793353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,10,21]]}},"alternative-id":["0965-0407(20131021)20:12L.545;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504013x13728687793353","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,21]]}}}